Endometrial cancer, also called uterine cancer, starts in the lining of the uterus. It is the most common gynecologic cancer in wealthy countries and affects women worldwide. Each year, more than 417,000 women are diagnosed globally.
Most women are diagnosed early because abnormal uterine bleeding, especially after menopause, is a common symptom. Early diagnosis greatly improves the chance of a cure, making endometrial cancer one of the most treatable solid tumors.
A cure means the cancer is completely gone and does not return over long-term follow-up, usually five years or more. Cure depends on how deep the tumor grows, whether lymph nodes are affected, and if cancer has spread to other organs.
Cure Rates by Stage
Stage I: Cancer is confined to the uterus. Cure rates are over 90–95% for low-grade tumors treated with surgery.
Stage II: Cancer spreads to the cervix. Cure rates are 70–85%, depending on tumor type and risk factors.
Stage III: Cancer spreads beyond the uterus. Surgery, radiation, and chemotherapy can achieve 40–60% cure rates.
Stage IV: Cancer has distant metastases. Cure is rare but possible in select cases, especially with hormone-sensitive tumors or targeted therapies.
Surgery as the Primary Treatment
Surgery is the main treatment. Most patients undergo removal of the uterus, ovaries, and fallopian tubes. Complete surgical staging, including lymph node evaluation, is essential. Minimally invasive surgery often provides excellent results with fewer complications.
Radiation and Chemotherapy
Radiation helps reduce local recurrence for intermediate or high-risk patients. Chemotherapy, usually carboplatin plus paclitaxel, is recommended for high-grade or advanced tumors. These treatments improve survival and boost cure rates, especially in Stage II and III disease.
Molecular Subtypes Affect Prognosis
Endometrial cancer has different molecular subtypes:
- POLE-ultramutated: Very high cure rate (>95%), even in advanced stages.
- MSI-high: Intermediate prognosis, responds well to immunotherapy.
- Copy-number low: Generally good prognosis.
- Copy-number high / p53-abnormal: Aggressive, lower cure rates.
Knowing the tumor subtype helps doctors personalize treatment and better predict outcomes.
Advanced and Recurrent Cancer
Cure is more difficult in advanced or recurring disease. Immunotherapy helps some patients, especially those with MSI-high tumors. HER2-positive uterine cancers may respond to trastuzumab. A small number of patients achieve long-term remission even in metastatic disease.
Hormone Therapy
Endometrial cancer is hormone-driven. Early, low-grade tumors may be treated with hormone therapy to preserve fertility. Some patients can achieve cure after subsequent surgery. Hormone therapy also controls disease in hormone-sensitive metastatic cancer.
The Importance of Early Detection
Because abnormal bleeding is noticeable, endometrial cancer is often diagnosed early, leading to higher cure rates than ovarian or cervical cancer. People with hereditary risks, such as Lynch syndrome, require regular surveillance. Prompt evaluation of symptoms remains key to successful treatment.
Life After Endometrial Cancer
Most survivors live long, healthy lives. Follow-up focuses on detecting recurrence, managing side effects, and maintaining quality of life. Early-stage survivors usually enjoy excellent long-term wellbeing.
Conclusion
Endometrial cancer has one of the highest cure rates among gynecologic cancers. Advances in surgery, radiation, chemotherapy, hormone therapy, and immunotherapy are improving outcomes further. Molecular profiling allows more personalized care. Early detection and timely treatment give the majority of women a strong chance of long-term survival and excellent quality of life.
Related topics
